Ispecimen INC 8-K filings

iSpecimen Inc. reports the resignation of Wolf & Company, P.C. as their independent registered public accounting firm and the appointment of Bush & Associates CPA LLC as the new auditor, effective March 10, 2025.

iSpecimen Inc. amends its previous 8-K filing to disclose the finalized employment agreement with newly appointed President, Katharyn Field, including her compensation and terms of employment.

iSpecimen Inc. announces the appointment of Katharyn Field as President, the addition of Siyun Yang as an independent director, and Richard Paolone as Chair of the Board.

iSpecimen has secured suppliers for human metapneumovirus (hMPV) specimens, positioning itself to meet potential demand for research and vaccine development amid concerns of a COVID-style pandemic.

iSpecimen Inc. has appointed its Chief Executive Officer, Robert Bradley Lim, to the additional roles of Treasurer and Secretary, effective December 27, 2024.

iSpecimen Inc. has appointed a new CFO and announced a strategic shift towards procuring high-demand cancer biospecimens to support cancer research.

iSpecimen's Next Day Quote program is showing positive results, with a significant portion of sales now attributed to the program.

iSpecimen Inc. has appointed Robert Lim as its new Chief Executive Officer and a member of the Board of Directors, effective December 9, 2024.

iSpecimen Inc. reports the departure of CEO and CFO Tracy Curley, effective November 8, 2024, due to disagreements with the Board regarding the company's future direction.

iSpecimen Inc. successfully closed a $5 million public offering of common stock and pre-funded warrants and entered into a $2 million investor relations agreement.

iSpecimen Inc. is facing an arbitration claim from its former Chief Information Officer for $586,800 plus fees, while also regaining compliance with Nasdaq's minimum bid price requirement.

iSpecimen Inc. has entered into a $1 million loan agreement with a lender, resulting in a significant board restructuring and a potential future line of credit.

iSpecimen Inc. has announced a 1-for-20 reverse stock split, effective September 13, 2024, to increase its per share trading price and maintain its Nasdaq listing.

iSpecimen Inc. announced a 76% year-over-year increase in revenue for the second quarter of 2024, reaching approximately $2.86 million, driven by operational improvements and strategic initiatives.

iSpecimen Inc. reports the resignation of a director, the election of two new directors, and the approval of a reverse stock split at its annual meeting.

iSpecimen Inc. has announced the resignation of Benjamin Bielak as Chief Information Officer and Secretary, effective July 15, 2024.

iSpecimen Inc. has entered into a new five-year lease for office space in Woburn, MA, while simultaneously terminating its existing lease in Lexington, MA.

iSpecimen Inc. has set the date for its 2024 Annual Meeting of Stockholders for July 19, 2024, and established May 27, 2024, as the deadline for stockholder proposals.

iSpecimen reported its Q1 2024 financial results, highlighting progress with its 'Next Day Quotes' program despite a decrease in overall revenue.

iSpecimen Inc. has been granted a second extension until October 7, 2024, to regain compliance with Nasdaq's minimum bid price requirement.

iSpecimen Inc. has appointed Elizabeth A. Graham to its Board of Directors, filling a vacancy left by a previous resignation.

iSpecimen announced its 2023 financial results, highlighting a focus on profitability, operational efficiencies, and strategic growth initiatives.

iSpecimen Inc. has entered into an agreement to sell up to $1.5 million of its common stock through an at-the-market offering.

iSpecimen Inc. has entered into agreements to repurchase outstanding warrants for $0.04 per share, effectively terminating the warrants and related agreements.